Mesa Laboratories Inc. MLAB

SEC filings · Reporting currency USD · Quarterly reporting · Figures as of 2027-Q1 · updated 2026-09-04 · ISIN US59064R1095

Operating income doubled Net income turned positive Margin expanding strategy: Strategic pivot

The new quarter, in context. · We follow every stock through its original filings: the latest figures against their history, guidance against actuals; neutral, continuously updated, every figure clickable with its source.

AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more

AI-generatedCreated with AI assistance from the company's linked original filings (transparency per Art. 50 EU AI Act). More about the tool: Claude Code.

Not investment adviceNeutral financial information, no recommendation, no investment research within the meaning of MiFID II.

Verify yourselfFigures are extracted automatically, errors are possible. Every figure is clickable with its source; the issuer's original documents are always authoritative.

EditorialThe texts (business model, current status, development and others) are written AI-editorially from the original reports alone, cross-checked automatically and backed with sources; the company's own account, no assessment of our own. Methodology

AI research · This page works as a source-backed data basis for further research with AI assistants such as Claude; every figure remains verifiable via the source links.

Business Model#

What the company does and how it earns its money; written AI-editorially, exclusively from the company's original reports, without any assessment of our own.

Mesa Laboratories designs, manufactures, and distributes quality control products and services for highly regulated industries. The company operates through four reporting divisions: Sterilization and Disinfection Control, which produces biological and chemical indicators used to validate sterilization processes in healthcare and pharmaceutical settings; Calibration Solutions, which provides calibration instruments and associated services; Biopharmaceutical Development, offering immunoassay and analytical tools for biopharmaceutical research customers; and Clinical Genomics, which supplies molecular diagnostic products for clinical laboratory use. Revenue is generated through the sale of instruments, consumable products, and service contracts across these divisions, with a customer base spanning life sciences, healthcare, pharmaceutical manufacturing, and industrial sectors. The Biopharmaceutical Development segment carries a structural cost-currency mismatch, as expenses are incurred in Swedish Krona while revenues are generated predominantly in USD and EUR.

Current Status#

Summary of the most recent reporting period: core figures, drivers and management statements; written editorially from the current original report, every figure backed by a source number.

Mesa Laboratories reported total revenue of $60.1 million for 2027-Q1, a 1.0% increase year over year, with core organic revenue growth returning to positive at 0.4% ³⁰. Operating income rose to $7.0 million from $3.1 million in the prior-year period, and adjusted operating income reached $15.0 million ³⁰. Cash flows from operating activities increased to $14.7 million from $1.9 million in the comparable period, driven by improved collections and operating performance ¹⁵. The company reduced its Total Net Leverage Ratio to 1.85, below its stated 2.0 target, after repaying $8.7 million of debt during the quarter ³⁰. New CEO Siddhartha Kadia, who joined approximately 100 days prior to the report date, indicated that full-year guidance will be provided in November ³⁰.

Management commentary on the 2027-Q1 results (8-K-EX99.1, 2026-08-10):

„I joined Mesa about one hundred days ago. I did not spend my time writing a vision statement, I spent it inside the company, with our people and our customers. What I found is a set of durable, regulation-embedded franchises with real and growing earnings power, and fixable execution problems we have already begun to fix. My focus is disciplined execution and consistent, profitable growth across our four divisions. In November, alongside first-half results, I will give full-year guidance.“ – Siddhartha Kadia, President and Chief Executive Officer ³⁰

„We remain focused on disciplined capital allocation and preserving the financial flexibility necessary to support Mesa's strategic priorities.“ – John Sakys, Chief Financial Officer ³⁰

Revenue · 2027-Q160$m+1.0 % vs. 2026-Q1

Net profit · 2027-Q13$m−40.4 % vs. 2026-Q1

EPS · 2027-Q10.49$−42.4 % vs. 2026-Q1

Revenue trend

Guidance

For 2026-H1, the company guides Revenue to meet revenue goals (confirmed). ²⁶.

Profitability

Operating income increased 129.5% to $7.0 million compared to $3.1 million in the prior-year period, reflecting operating efficiencies and cost-containment initiatives ¹⁵. Net income for the quarter was $2.8 million, with diluted EPS of $0.49. Gross profit margin expanded 290 basis points to 64.9%, primarily due to lower third-party contracted labor spend, supply chain efficiency improvements, and favorable product mix ¹⁵.

Leverage

Cash at quarter-end was $30.7 million, with net debt of $35.4 million. The company repaid $8.7 million of debt during the quarter, reducing the Total Net Leverage Ratio to 1.85, below its 2.0 target ³⁰. Additionally, $97.0 million in Notes were repaid using borrowings under the Credit Facility's Revolver, replacing higher-interest debt with Revolver borrowings ¹⁵.

Management view

New CEO Siddhartha Kadia, who joined approximately 100 days prior to the earnings report, is guiding the company's operational direction, with full-year guidance expected to be communicated in November ³⁰. Core organic revenue growth returned to positive territory at 0.4%, supported by strong commercial execution in Calibration Solutions, which grew 7.6% organically ³⁰. Biopharmaceutical Development revenues grew 5.0% organically in the quarter, driven by higher immunoassay hardware and consumables sales ³⁰.

Change

The Sterilization and Disinfection Control division reported a 3.6% revenue decline to $24.5 million, attributed to fulfillment and delivery execution challenges that impacted customer shipments ¹⁵. Clinical Genomics revenue was essentially flat at $10.3 million, as modest growth outside China was offset by continued weakness in that market, though the year-over-year revenue reduction in China was significantly smaller than in the prior-year period ¹⁵. Total operating expenses decreased 5.6%, primarily due to lower stock-based compensation expense; excluding stock-based compensation, operating expenses decreased 1.5% ¹⁵.

Risks (current)

Fulfillment and delivery execution challenges in the Sterilization and Disinfection Control division continue to affect customer shipments and segment revenue ³⁰. Continued weakness in the China market, particularly within Clinical Genomics, presents an ongoing revenue headwind, though the rate of decline moderated relative to prior periods ³⁰. Goodwill and intangible assets of $270.2 million carry potential impairment risk, significant debt obligations require substantial ongoing cash flow, the Biopharmaceutical Development segment bears a structural SEK cost versus USD/EUR revenue currency mismatch, and outstanding legal proceedings represent additional financial exposures ¹⁴ ³⁰.

Price & Chart#

Interactive price chart (TradingView) and the trend of key figures from the core tables. The price chart loads only after a click; at that point a connection to TradingView is established.

Daily candles with news and earnings markers. Loads only on click.

Advertisement · affiliate links; we may earn a commissionAffiliate partnerships help us keep these reports free and regularly updated.

Share-Price Drivers#

Factors the company itself names as material for its business development (IR-based); reproduced neutrally, no price forecast and no assessment of our own.

Four-segment specialty portfolio led by Sterilization and Disinfection Control
Sterilization and Disinfection Control is the largest reportable segment at $24.5M of $60.1M total quarterly revenue, so its trajectory dominates group results; total revenue grew 1.0% to $60.1M with a 64.9% margin (³⁰, ¹⁵)

Sterilization and Disinfection Control segment
Largest segment at $24.5M in 2027-Q1, up 3.6% year-on-year (³⁰)

Calibration Solutions segment
Fastest-growing segment at $13.3M, up 7.6% in 2027-Q1 (³⁰)

Clinical Genomics segment
Segment revenue essentially flat at $10.3M (+0.1%) in 2027-Q1; division under strategic-plan deployment (Breakthrough 7) and prior restructuring, with Veridose 2.0 launched and New Product Development being accelerated (³⁰, ²⁶, ²⁵)

GKE acquisition integration and U.S. market access
GKE (GKE GmbH, SAL GmbH, Beijing GKE) acquired 2023 and integrating; company pursuing 510(k) regulatory clearance to open U.S. sales of GKE products (¹⁴)

Deleveraging / balance-sheet normalization
Net debt fell from $146.5M in 2026-Q1 to $35.4M in 2027-Q1 following the Convertible Senior Notes settlement in 2025-08 (³⁰, ¹⁴)

Adjusted operating profitability
Adjusted operating income rose to $15.0M in 2027-Q1 from $12.9M a year earlier, with free cash flow of $14.2M (³⁰)

Biopharmaceutical Development segment
Segment revenue of $12.1M, up 5.0% in 2027-Q1 (³⁰)

Sector trend: Group gross/blended margin stands at 64.9% with adjusted operating income and free cash flow rising, indicating firming profitability; underlying demand across sterilization, calibration and biopharmaceutical lines is growing low-to-mid single digits while clinical genomics demand is flat (³⁰, ¹⁵).

Event Timeline#

This timeline collects the material events from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements. Events are grouped by quarter (most recent first); the grey tag before each event names the event type, the date is the publication date of the source. Management quotes open the quarter block as direct quotes. Per quarter we show the three most defining events; more can be expanded per quarter, older years are collapsed. Every event carries its source as a superscript, clickable number.

Overview: one dot per event · click jumps to the period

2027 · 7 events

2027-Q1 · Apr – Jun 2026

„As announced in March, I am in the middle of my onboarding journey as I am conducting my first 100 days review of the businesses since joining Mesa on April 13. I want to share that I am even more excited today than the day I joined. The Mesa diversified platform has tremendous potential to create shareholder value while delivering on our promise to Protect the Vulnerable. Upon completion of my 100-day review of our business, I am looking forward to begin meeting with our shareholders and discussing my vision for the Company moving forward. I also expect to be in position to provide rest of the year guidance along with the release of H1 results.“ – Siddhartha Kadia, President and CEO ²⁹

earnings 2026-08-10
Operating income increased 129.5% to $7.0M from $3.1M, driven by operating efficiencies and cost-containment initiatives ¹⁵

Operating income doubled 2026-08-10
Operating income more than doubled YoY (3.1 to 7.0 USDm, +126%). ¹⁵

Margin expanding 2026-08-10
Gross profit margin expanded 290 basis points to 64.9%, driven by lower third-party contracted labor spend, supply chain efficiency improvements, and favorable product mix ¹⁵

Strategic pivot 2026-08-10
New CEO Siddhartha Kadia approximately 100 days into role; full-year guidance deferred to November ³⁰

Net income turned positive 2026-05-27
Full-year net income of $6.7M versus prior-year loss of $1.9M; 440% increase; diluted EPS $1.21 ²⁹ ¹⁴

Margin expanding 2026-05-27
Non-GAAP AOI margin expanded 200bps to 25.5% of revenues; consolidated gross profit margin improved 0.9pp to 63.5% ²⁹ ¹⁴

Strategic pivot 2026-05-27
Siddhartha Kadia appointed President and CEO effective April 13, 2026, initiating 100-day business review ²⁹

2026 · 14 events

FY2026 · Apr 2025 – Mar 2026

Net income turned positive 2026-05-27
Net income turned positive for the first time after 2 negative fiscal years (-2.0 to +6.7 USDm). ²⁹

2026-Q3 · Oct – Dec 2025

„While macro conditions in the first three quarters of FY26 were challenging, we remain encouraged that end markets are stabilizing, our innovative solutions remain top of mind with customers, and our highly adaptable operating model and team will enable us to further accelerate both top and bottom-line growth as market conditions improve“ – Gary Owens, Chief Executive Officer ²⁸

earnings 2026-02-03
Net income of $3.6M versus prior-year Q3 loss of $1.7M; operating income increased 38.0% to $8.0M ¹³ ²⁸

Revenue accelerating ◦ 2026-02-03
Biopharmaceutical Development revenues grew 17.5% organically driven by higher Immunoassays and Peptides volumes ¹³ ²⁸

Margin expanding 2026-02-03
Consolidated gross profit margin improved to 64.2% from 63.3% in prior-year Q3; Clinical Genomics gross margin improved to 60.5% despite lower revenues ¹³

2026-Q2 · Jul – Sep 2025

„While the first half of FY26 was full of many challenges, we are encouraged by the faith that our customers place in our solutions and team, our traction with key initiatives, the demonstrated strength of our operating model, and the resilience of our team“ – Gary Owens, Chief Executive Officer ²⁷

Revenue accelerating ◦ 2025-11-06
Consolidated revenues grew 5.0% to $60.7M with 3.7% core organic growth; Biopharmaceutical Development consumables revenues up approximately 14% ¹² ²⁷

revenue 2025-11-06
Clinical Genomics China revenues contracted approximately 58% due to macroeconomic, tariff, and regulatory headwinds; continued decreases expected for remainder of fiscal year ²⁷

Strategic pivot 2025-11-06
Company implemented $3.2M annualized cost reduction initiative; $2.1M from Clinical Genomics, with $2.3M net annualized savings after reinvestment in Sterilization and Disinfection Control ¹² ²⁷

2026-Q1 · Apr – Jun 2025

„While 1Q26 was challenging in the face of a difficult macroeconomic environment, we are encouraged by our continuing commercial success, traction with key initiatives, and the resilience of our operating model“ – Gary Owens, Chief Executive Officer ²⁶

„We were pleased to realize several important strategic milestones during FY25 including: 1) exceeding our acquisition commitment for the first twelve months of full ownership of GKE for both revenues and profitability, 2) fully integrating GKE into our corporate infrastructure within nine months, 3) launching Veridose 2.0 in the CG division, our most comprehensive PGx panel to date, 4) implementing Salesforce CRM across the sales teams in all four divisions, 5) gaining solid traction with our Commercial Excellence initiatives as evidenced by accelerated bookings growth, and 6) accelerating traction with the Mesa Way by completing 45 discrete process improvement events, a new Mesa record“ – Mr. Owens ²⁵

Revenue decelerating ◦ 2025-08-05
Clinical Genomics revenues fell 9.7% (10.7% core organic decline) on $1.8M China revenue contraction (69% decline) due to macroeconomic and regulatory uncertainty ¹¹ ²⁶

Net income turned positive 2025-08-05
Net income turned positive for the first time after 2 negative periods (-7.1 to +4.7 USDm). ¹¹

Margin compressing 2025-08-05
Gross profit margin declined 2.0pp to 62.0%; AOI margin fell to 21.7% from 26.4%, driven by tariff charges and FX impacts ¹¹ ²⁶

Revenue accelerating ◦ 2025-08-05
Sterilization and Disinfection Control revenues grew 10.7% with 7.5% core organic growth via strong commercial execution ¹¹ ²⁶

earnings 2025-05-28
Full-year operating income improved to $16.3M; prior year included a $274.5M impairment loss (base effect) – adjusted operating income grew 12.3% for the year ¹⁰ ²⁵

Revenue accelerating ◦ 2025-05-28
Full-year revenues rose 11.5% to $241.0M with 5.0% core organic growth; all four divisions delivered core organic revenue growth in Q4 FY2025 for the first time in the fiscal year ²⁵

Acquisition 2025-05-28
GKE acquisition fully integrated within nine months; contributed $24.8M revenues in FY2025 and exceeded initial revenue and profitability commitments ²⁵

2025 · 10 events

FY2025 · Apr 2024 – Mar 2025

Operating income turned positive 2025-05-28
Operating income turned positive for the first time after 1 negative fiscal year (-272.1 to +16.3 USDm). ²⁵

2025-Q4 · Jan – Mar 2025

Revenue decelerating 2026-05-27
Revenue growth decelerated to +5.4% YoY (prior period +17.4%). ²⁹

2025-Q3 · Oct – Dec 2024

„Profitability for the quarter as measured by our primary metric of AOI excluding unusual items grew by 13.3% versus the prior year to $14,788. Versus prior year, gross profit percentage expanded by 80 bps but shrank by 240 bps when excluding the impact of non-cash charges. The contraction was primarily due to both product and geographical mix.“ – Gary Owens, Chief Executive Officer ²⁴

earnings 2025-02-04
Operating income improved to $5.8M in Q3 from a loss of $67K in Q3 FY2024; adjusted operating income grew 13.3% to $14.8M with 23.5% margin ²⁴

Revenue accelerating ◦ 2025-02-04
Revenues increased 17.5% to $62.8M in Q3 with core organic growth of 13.2%; Biopharmaceutical Development grew 31.3% organically and Calibration Solutions grew 18.9% organically ²⁴

2025-Q2 · Jul – Sep 2024

„Profitability as measured by our primary metric of AOI excluding unusual items grew by 18.9% versus the prior year to $14,352, a 210 bps expansion when expressed as a percentage of revenue. Versus prior year, gross profit percentage expanded by 90 bps but shrank by 40 bps when excluding the impact of non-cash charges primarily due to mix.“ – Gary Owens, Chief Executive Officer ²³

earnings 2024-11-07
Operating income reached $3.5M in Q2 versus a loss of $60K in the prior year quarter; non-GAAP adjusted operating margin expanded 210 basis points to 24.8% of revenues ²³

Revenue accelerating ◦ 2024-11-07
Biopharmaceutical Development revenues increased 28.9% in Q2 driven by increased capital equipment spending in North America and Europe; core organic growth of 27.9% ²³

Revenue decelerating ◦ 2024-11-07
Clinical Genomics revenues declined 26.0% in Q2 due to China economic slowdown and U.S. regulatory challenges on lab-developed tests; core organic decline of 26.5% ⁸

2025-Q1 · Apr – Jun 2024

„Looking forward, we are hopeful that our biopharmaceutical related end markets will continue the strength exhibited in 4Q24 and 1Q25. In any market scenario we will work diligently so that our differentiated products, strategic initiatives and the Mesa Way operating model enable us to outperform,“ – Gary Owens, Chief Executive Officer ²²

Operating income turned positive 2024-08-05
Operating income improved to $5.6M in Q1 from a loss of $664K in the prior year quarter; adjusted operating income rose 47% to $15.3M or 26.4% of revenues ²²

Revenue accelerating ◦ 2024-08-05
Total revenues rose 14.9% to $58.2M in Q1; GKE contributed 12.4% inorganic growth and core organic growth was 2.5%, led by 21.4% organic growth in Biopharmaceutical Development ²²

Margin expanding 2024-08-05
Gross profit margin expanded 250 basis points to 64.0% in Q1; excluding non-cash charges, expansion was 150 basis points ²²

2024 · 13 events

2024-Q4 · Jan – Mar 2024

„Annual revenues of $216,187 decreased by 1.3% versus the prior year, driven by a decline in core organic revenues of 5.4%, partially offset by GKE revenues of $9,289. Core organic headwinds were primarily in BPD and CG which offset growth in both SDC and CS. Specifically, BPD faced the softening of demand for capital equipment in the biopharmaceutical vertical, while CG incurred headwinds from the previously announced loss of Sema4 as a customer at the end of the second quarter in FY23 and the ongoing impact of the economic slowdown in China,“ – Gary Owens, Chief Executive Officer ²¹

Net income turned negative ◦ 2024-06-05
Recorded $274.5 million non-cash impairment on goodwill and long-lived assets: $236.4 million in Clinical Genomics and $38.2 million in Biopharmaceutical Development divisions, driving FY2024 GAAP net loss of $254.2 million (²¹, ⁶)

Revenue decelerating ◦ 2024-06-05
Q4 revenues increased 6% to $58.9 million, with headline growth driven by GKE contribution of $5.5 million; core organic revenues declined 3.5% (²¹)

Strategic pivot 2024-06-05
Clinical Genomics division restructured under new General Manager; 17 positions eliminated with expected annual savings of approximately $3.0 million; updated business strategy implemented (²¹)

2024-Q3 · Oct – Dec 2023

„We were pleased to add GKE to our Sterilization & Disinfection Control division as their high-quality chemical indicators and healthcare channels are highly complementary to our traditional strengths in biological indicators and life science channels. Looking ahead, with ongoing economic uncertainty, we will be conservative in deploying any increases in operating expenses.“ – Gary Owens, Chief Executive Officer ²⁰

Revenue decelerating ◦ 2024-02-05
Organic revenues declined 8.6%; Clinical Genomics down 19.5% driven by China economic slowdown and healthcare anti-corruption initiatives; Biopharmaceutical Development down 19.1% on constrained capital equipment placements (²⁰)

Revenue accelerating ◦ 2024-02-05
Calibration Solutions organic revenue growth of 12.9% with gross margin expansion of 600 basis points as prior-year supply chain constraints continued to abate (²⁰)

Net income turned positive 2024-02-05
Net income turned positive for the first time after 2 negative periods (-1.2 to +2.1 USDm). ⁵

2024-Q2 · Jul – Sep 2023

„profitability for 2Q24, as measured by our primary metric of adjusted operating income excluding unusual items was $11,163, a decrease of 29.1% quarter over quarter primarily due to the decreased revenues. This number however did increase by 17.2% sequentially from 1Q24 primarily due to increases in revenues. Additionally, during 2Q24 we implemented cost control actions taken in response to the unclear macroeconomic environment and the specific slow-down in the biopharmaceutical vertical which are expected to generate annual savings of approximately $2,000 starting in 3Q24.“ – Gary Owens, Chief Executive Officer ¹⁹

Revenue decelerating ◦ 2023-11-06
Revenues declined 9.5% to $53.2 million; core organic down 10.1%, with approximately $8.2 million annual headwind from prior-year Sema4 customer loss in Clinical Genomics and continued softening in capital equipment demand (¹⁹)

Margin compressing 2023-11-06
Clinical Genomics gross margin declined 800 basis points to 49.7%, falling below long-term target of high 50s to low 60s, on lower revenue absorption following Sema4 loss (¹⁹)

Acquisition 2023-11-06
GKE acquisition completed October 2023, expanding Sterilization and Disinfection Control with chemical sterilization indicators and biologics portfolio; credit facility expanded from $75 million to $125 million to partially fund the deal (⁴)

2024-Q1 · Apr – Jun 2023

„We are pleased to see our Calibration Solutions division return to growth as our supply chain issues abate, that the Clinical Genomics business systems pipeline continues to grow in North America, and that our overall business in China remains robust. Given ongoing economic uncertainty, we will be conservative in deploying operating expenses.“ – Gary Owens, Chief Executive Officer ¹⁸

earnings 2023-08-03
Operating loss improved 85.5% to $(664) thousand from $(4,594) thousand, primarily due to resolution of prior-year labor shortages and supply chain difficulties in Calibration Solutions and Sterilization and Disinfection Control (¹⁸)

Revenue accelerating 2023-08-03
Calibration Solutions revenues +12%, driven by abatement of prior-year supply chain disruptions and labor shortages that had constrained production (³)

Revenue decelerating ◦ 2023-08-03
Biopharmaceutical Development organic decline of 10.3% on softening demand for capital equipment; segment viewed as unlikely to grow at historical rates in FY2024 (³)

Margin expanding 2023-05-30
Full-year gross profit margin expanded 2 percentage points to 61%; prior-year FY2022 base included $7.5M Agena acquisition inventory step-up charge that did not recur, partially offset by unfavorable product mix and adverse foreign currency ²

Key Figures ($m)#

The company's core financial figures in three views, one below the other: fiscal years (as reported; after restatements the table shows the most recent filing version, marked), half-years (6-month basis, H2 = second half on its own) and quarters (3-month basis, not cumulative). Each row is one period, most recent first. Values with a dotted underline are clickable and show the raw value, the exact source location, the scale evidence and the source; derived values additionally show their formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.

All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.

Basis Metric

Revenue ($m) · annual basis, as reported

Net income ($m) · annual basis, as reported

EPS ($) · annual basis, as reported

Operating cash flow ($m) · annual basis, as reported

Revenue ($m) · quarterly basis, as reported

Net income ($m) · quarterly basis, as reported

EPS ($) · quarterly basis, as reported

Operating cash flow ($m) · quarterly basis, as reported

Cash ($m) · annual basis, as reported

Capex ($m) · annual basis, as reported

FCF ($m) · annual basis, as reported

D&A ($m) · annual basis, as reported

Cash ($m) · quarterly basis, as reported

Debt ($m) · quarterly basis, as reported

Net Debt ($m) · quarterly basis, as reported

Capex ($m) · quarterly basis, as reported

FCF ($m) · quarterly basis, as reported

D&A ($m) · quarterly basis, as reported

Shown: the most recent fiscal years. Full history since FY2016 is on record.

Fiscal years

Amounts in $m · EPS in $ per share · as reported

Period	Calendar quarter	Revenue	Op. income	Op. income (adj.)	Net income	EPS ($)	OCF	Source
FY2026	Q2/2025–Q1/2026	249.1	18.5	63.49	6.7	1.21	42.8	²⁹
FY2025	Q2/2024–Q1/2025	241	16.3	54.01	-2	-0.36	46.8	²⁵
FY2024	Q2/2023–Q1/2024	216.2	-272.1	50.51	-254.2	-47.20	44.1	²¹

Quarters

Amounts in $m · EPS in $ per share · Net Debt/EBITDA as a multiple · as reported

Period	Calendar quarter	Published	Revenue	Op. income	Op. income (adj.)	Net income	EPS ($)	FCF	Cash	Net Debt	Net Debt/EBITDA (x)	Source
2027-Q1*	Q2/2026	2026-08-10	60.1	7	15	2.8	0.49	14.2	30.7	35.4	0.8x (LTM)	¹⁵
2026-Q4*	Q1/2026	2026-05-27	63.7	2.7	18.3	-4.1	-0.75*	13.5	26.9	40.6	1x (LTM)	²⁹
2026-Q3*	Q4/2025	2026-02-03	65.1	8	17.1	3.6	0.65	18	29	39.5	0.9x (LTM)	¹³
2026-Q2*	Q3/2025	2025-11-06	60.7	4.7	15.2	2.5	0.45	7.1	20.4	49	1.2x (LTM)	¹²
2026-Q1*	Q2/2025	2025-08-05	59.5	3.1	12.9	4.7	0.85	0.9	21.3	146.5	3.8x (LTM)	¹¹
2025-Q4*	Q1/2025	2026-05-27	62.1	1.5	12.3	-7.1	-1.30*	11.9	27.3	141.2	3.5x (LTM)	²⁹
2025-Q3*	Q4/2024	2025-02-04	62.8	5.8	14.5	-1.7	-0.31	17.3	27.3	142.2	–	⁹
2025-Q2*	Q3/2024	2024-11-07	57.8	3.5	14.4	3.4	0.63	3.5	24.3	145.8	–	⁸
2025-Q1*	Q2/2024	2024-08-05	58.2	5.6	14	3.4	0.62	9.9	28.5	45.6	–	⁷
2024-Q4*	Q1/2024	2025-05-28	58.9	-271.3	12.3	-254.6^~	-47.26*	12.3	28.2	–	–	¹⁰
2024-Q3*	Q4/2023	2024-02-05	53.5	-0.1	12	2.1	0.39	10.4	28.2	–	–	⁵
2024-Q2*	Q3/2023	2023-11-06	53.2	-0.1	10.3	-1.2	-0.23	9.1	35.6	–	–	⁴
2024-Q1*	Q2/2023	2023-08-03	50.6	-0.7	10.4	-0.5	-0.10	9.7	32.4	–	–	³

* derived: values with formula provenance (hover); Q4 = FY − 9M · H2 = FY − H1 · EPS via implied shares · net debt = financial debt − cash · FCF = OCF − |capex|.

Columns not reported in this reporting cadence are hidden: EBITDA (adj.), EPS adj. (not reported in any source for these periods).

Balance Sheet & Cash Flow ($m)#

Point-in-time balance sheet items (e.g. cash, financial debt) and cash flow items (operating cash flow, investments/capex) per fiscal year, half-year and quarter. Balance sheet values are as of the period end, flow items cover the period. Derived values are marked and are calculated, for example, as: net debt = financial debt − cash; free cash flow = operating cash flow − capex; the click popover shows formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.

Fiscal years

Amounts in $m · as reported

Period	Calendar quarter	Published	Cash	Debt	Net Debt	D&A	OCF	Capex	FCF	Source
FY2026	Q2/2025–Q1/2026	2026-05-27	26.9	67.5	40.6	23.3	42.8	3.2	39.6	²⁹
FY2025	Q2/2024–Q1/2025	2025-05-28	27.3	168.5	141.2	24.5	46.8	4.2	42.6	¹⁰
FY2024	Q2/2023–Q1/2024	2024-06-28	28.2	–	–	31.6	44.1	2.6	41.6	⁶

Quarters

Amounts in $m · as reported

Period	Calendar quarter	Published	Cash	Debt	Net Debt	D&A	OCF	Capex	FCF	Source
2027-Q1	Q2/2026	2026-08-10	30.7	66.1	35.4	5.6	14.7	0.6	14.2	¹⁵
2026-Q4	Q1/2026	2026-05-27	26.9	67.5	40.6	5.8	14	0.4	13.5	²⁹
2026-Q3	Q4/2025	2026-02-03	29	68.4	39.5	5.7	18.8	0.7	18	¹³
2026-Q2	Q3/2025	2025-11-06	20.4	69.4	49	5.8	8.2	1.1	7.1	¹²
2026-Q1	Q2/2025	2025-08-05	21.3	167.7	146.5	6	1.9	1	0.9	¹¹
2025-Q4	Q1/2025	2026-05-27	27.3	168.5	141.2	7.5	12.7	0.8	11.9	²⁹
2025-Q3	Q4/2024	2025-02-04	27.3	169.5	142.2	5.5	18.1	0.8	17.3	⁹
2025-Q2	Q3/2024	2024-11-07	24.3	170.2	145.8	6.1	5.3	1.8	3.5	⁸
2025-Q1	Q2/2024	2024-08-05	28.5	74.1	45.6	5.5	10.7	0.9	9.9	⁷
2024-Q4	Q1/2024	2025-05-28	28.2	–	–	6.3	12.9	0.5	12.3	¹⁰
2024-Q3	Q4/2023	2024-02-05	28.2	–	–	9	11.5	1.1	10.4	⁵
2024-Q2	Q3/2023	2023-11-06	35.6	–	–	8.1	9.8	0.6	9.1	⁴
2024-Q1	Q2/2023	2023-08-03	32.4	–	–	8.1	9.9	0.3	9.7	³

Debt = long-term + current · Net debt = debt − cash · FCF = OCF − capex.

Revenue by Type (as of 2027-Q1 · USDm · 5/6)#

Revenue split by segment or product type, exactly as the company itself reports it. The basis is stated next to each value (3, 6 or 12 months); segment totals can deviate from group revenue (reconciliation/consolidation items). If the company changes its segment structure, older structures are kept in the expandable part. Rows in grey are no longer reported separately by the company; they show the last available figures and are never extrapolated.

Segment	Since	Period	Basis	Revenue	Growth	Margin	Source
Sterilization and Disinfection Control	FY2022	2027-Q1	3M	24.5	3.6%	–	³⁰
Calibration Solutions	FY2022	2027-Q1	3M	13.3	7.6%	–	³⁰
Biopharmaceutical Development	FY2022	2027-Q1	3M	12.1	5%	–	³⁰
Clinical Genomics	FY2022	2027-Q1	3M	10.3	0.1%	–	³⁰
Total	2026-Q1	2027-Q1	3M	60.1	1%	64.9%	¹⁵
Mesa's reportable segments	2023-Q1	2025-Q3	9M	178.8	4.3%	62.9%	⁹

Products & M&A (3/10 active+recent)#

Product announcements from the reports; market launches, approvals, partnerships; with first mention (date) and source. “Active/current” means: still mentioned in the most recent reports; what the company no longer mentions moves to the expandable part but is never deleted. Rows in grey are discontinued products.

Product/Line	Since	Status	Source
New Product Development acceleration in Clinical Genomics	2026-03	Launched	²⁶
Peptide system export controls	2026	Launched	²⁹
GKE 510(k) regulatory clearance pursuit for US market	2026	Launched	¹⁴
Clinical Genomics division strategic plan deployment (Breakthrough 7)	2025-05	Launched	²⁶
Veridose 2.0 launch in Clinical Genomics division	2025	Launched	²⁵
Salesforce CRM implementation across sales teams	2025	Launched	²⁵
510(k) clearance for certain GKE products in United States (3x)	2024-09	Launched	¹⁰
FDA regulatory approval for certain GKE products for U.S. sale	2024	Launched	⁶
Class III IVD panel approval - pharmacogenetics (4x)	2023-01	Launched	²
PurePep EasyClean products launch	2023	Launched	²

M&A (9)#

All recorded acquisitions (purchases) and divestitures/exits with date, short description and source; deliberately including smaller transactions that summaries often miss. Purchase prices appear only where the company itself has disclosed them. Rows in grey are cancelled transactions; the cancellation date is shown in the row.

Acquisitions · 7Divestitures/exits · 1older: 1 (in the table)

Acquisitions

Transaction / stake	Date	Type	Source
Convertible senior notes repurchase (2x)	2025-08	Completed	¹⁰
2025 Notes repurchase	2024-04	Completed	⁶
Belyntic contingent consideration (2x)	2024-03	Completed	⁸
GKE acquisition (4x)	2023-10	Completed	¹¹
GKE GmbH, SAL GmbH and Beijing GKE Science & Technology Co. Ltd. acquisition (2x)	2023-10	Completed	¹⁴
Belyntic peptide purification business acquisition	2022-11	Completed	⁶
Belyntic acquisition	2022-10	Completed	²
Agena acquisition (2x)	2021-10	Completed	²

Divestitures / exits

Transaction / stake	Date	Type	Source
Sema4 expanded carrier screening closure (2x)	2022-10	Divested	¹⁹

Reported KPIs (as disclosed) (131)#

Figures the company discloses itself in addition to the standard financials; order intake, recurring revenue, user or unit counts, adjusted measures. These “story KPIs” usually slip through standard databases; here they are collected as reported, with no calculation of our own. Important: the definition comes from the company itself and can differ from firm to firm; period and source are stated next to every value.

Company-specific KPIs verbatim from the filings (English, as disclosed; not normalised). Balance-sheet and boilerplate items filtered.

Date	Period	KPI	Value / change	Source
2026-08-10	2027-Q1	working capital	45.5 (USD in millions)	¹⁵
2026-08-10	2027-Q1	revolver outstanding	77.3	¹⁵
2026-08-10	2027-Q1	revolver borrowing capacity	125.0	¹⁵
2026-08-10	2027-Q1	required principal debt payments 12m	5.6 (USD in millions)	¹⁵
2026-08-10	2027-Q1	expected cash interest expense 12m	7.9 (USD in millions)	¹⁵
2026-08-10	2027-Q1	dividend per share	0.16	¹⁵
2026-08-10	2027-Q1	cash	30.7 (USD in millions)	¹⁵
2026-08-10	2027-Q1	Total Net Leverage Ratio	1.85	³⁰
2026-06-03	FY2026	working capital	$44.4 million	¹⁴
2026-06-03	FY2026	revolver outstanding	$84.5 million	¹⁴
2026-06-03	FY2026	non-US sales percentage	45%	¹⁴
2026-06-03	FY2026	GKE seller settlement April 2025	$9,555	¹⁴
2026-06-03	FY2026	GKE acquisition total consideration	$87,187	¹⁴
2026-06-03	FY2026	Dialyguard gross profit margin percentage	one-third	¹⁴
2026-06-03	FY2026	Dialyguard Calibration Solutions revenue percentage	approximately 30%	¹⁴
2026-06-03	FY2026	Clinical Genomics single customer revenue concentration	approximately 20%	¹⁴
2026-06-03	FY2026	Clinical Genomics consumables revenue percentage	approximately 80%	¹⁴
2026-06-03	FY2026	China Sales Percentage	approximately 8%	¹⁴
2026-06-03	FY2026	Cash Provided by Operating Activities	42,831 (USD in thousands)	¹⁴
2026-06-03	FY2026	Cash on Hand	$26.9 million	¹⁴
2026-06-03	FY2026	Biopharmaceutical Development Hardware Revenue Percentage	Approximately 40%	¹⁴
2026-06-03	FY2026	Biopharmaceutical Development Consumables Revenue Percentage	about 35%	¹⁴
2026-06-03	FY2026	Backlog Sterilization Disinfection	decreased by approximately $1.2 million	¹⁴
2026-06-03	FY2026	Backlog March 31 2026	approximately $33.6 million	¹⁴
2026-06-03	FY2026	Backlog March 31 2025	$43.2 million	¹⁴
2026-05-27	FY2026	Total Net Leverage Ratio	2.11	²⁹
2026-05-27	FY2026	AOI per share - diluted (Year Ended March 31, 2026)	10.72	²⁹
2026-05-27	FY2026	AOI per share - diluted	2.76	²⁹
2026-05-27	FY2026	AOI excluding unusual items per share - diluted (Year Ended March 31, 2026)	11.41	²⁹
2026-05-27	FY2026	AOI excluding unusual items per share - diluted	3.30	²⁹
2026-02-03	2026-Q3	Working Capital	51.2 million	¹³
2026-02-03	2026-Q3	Total Net Leverage Ratio	2.62	²⁸
2026-02-03	2026-Q3	Revolver Available	26.7 million	¹³
2026-02-03	2026-Q3	Cash	29.0 million	¹³
2025-11-06	2026-Q2	working capital	49.1 million	¹²
2025-11-06	2026-Q2	revolver outstanding	106.0 million	¹²
2025-11-06	2026-Q2	Quarterly Dividend per Share	0.16	¹²
2025-11-06	2026-Q2	Cash on Hand	20.4 million	¹²
2025-11-06	2026-Q2	Bookings	approximately 5% greater than revenues	¹²
2025-11-06	2026-Q2	Total Net Leverage Ratio	3.02	²⁷
2025-08-05	2026-Q1	Total Net Leverage Ratio	3.16	²⁶
2025-08-05	2026-Q1	Dividends per Share	0.16	¹¹
2025-05-28	FY2025	working capital	$(61.3) million	¹⁰
2025-05-28	FY2025	Revolver Available	115.0 million	¹⁰
2025-05-28	FY2025	Convertible Notes Outstanding	97.5 million	¹⁰
2025-05-28	FY2025	Cash and Cash Equivalents	27.3 million	¹⁰
2025-05-28	FY2025	Backlog	43.2 million	¹⁰
2025-05-28	FY2025	Recurring revenue mix (FY25)	~75%	²⁵
2025-05-28	FY2025	Past due backlog change (Q4 vs Q3)	27% decrease	²⁵
2025-05-28	FY2025	Past due backlog (SDC division, March 31, 2025)	approximately $2,000 higher	²⁵
2025-05-28	FY2025	Operating income margin (Q4)	2.4%	²⁵
2025-05-28	FY2025	Operating income margin (FY)	6.8%	²⁵
2025-05-28	FY2025	Net Leverage Ratio	3.01	²⁵
2025-05-28	FY2025	Free cash flow	42,559 (USD in thousands)	²⁵
2025-05-28	FY2025	Core organic revenues growth (Q4)	6.3%	²⁵
2025-05-28	FY2025	Core organic revenues growth (FY)	5.0%	²⁵
2025-05-28	FY2025	Cash flows from operations	46,808	²⁵
2025-05-28	FY2025	AOI as percentage of revenues (Q4)	19.7%	²⁵
2025-05-28	FY2025	AOI as percentage of revenues (FY)	23.5%	²⁵
2025-02-04	2025-Q3	Total Net Leverage Ratio	3.20	²⁴
2025-02-04	2025-Q3	Sterilization and Disinfection Control Organic Growth 9M Prior	1.0%	⁹
2025-02-04	2025-Q3	Sterilization and Disinfection Control Organic Growth 9M	2.9%	⁹
2025-02-04	2025-Q3	Sterilization and Disinfection Control organic growth 3m prior	(4.8%)	⁹
2025-02-04	2025-Q3	Sterilization and Disinfection Control organic growth 3m	7.8%	⁹
2025-02-04	2025-Q3	Clinical Genomics organic growth 9m prior	(14.6%)	⁹
2025-02-04	2025-Q3	Clinical Genomics organic growth 9m	(14.2%)	⁹
2025-02-04	2025-Q3	Clinical Genomics organic growth 3m prior	(19.5%)	⁹
2025-02-04	2025-Q3	Clinical Genomics organic growth 3m	1.0%	⁹
2025-02-04	2025-Q3	Calibration Solutions organic growth 9m prior	8.6%	⁹
2025-02-04	2025-Q3	Calibration Solutions organic growth 9m	10.1%	⁹
2025-02-04	2025-Q3	Calibration Solutions organic growth 3m prior	12.9%	⁹
2025-02-04	2025-Q3	Calibration Solutions organic growth 3m	18.7%	⁹
2025-02-04	2025-Q3	Biopharmaceutical Development organic growth 9m prior	(18.2%)	⁹
2025-02-04	2025-Q3	Biopharmaceutical Development organic growth 9m	26.6%	⁹
2025-02-04	2025-Q3	Biopharmaceutical Development organic growth 3m prior	(19.1%)	⁹
2025-02-04	2025-Q3	Biopharmaceutical Development organic growth 3m	29.8%	⁹
2024-11-07	2025-Q2	working capital	(45,252)	⁸
2024-11-07	2025-Q2	cash and equivalents	24,337 (USD in thousands)	⁸
2024-11-07	2025-Q2	Net Leverage Ratio	3.26	²³
2024-11-07	2025-Q2	AOI margin excluding unusual items pct	24.8%	²³
2024-08-05	2025-Q1	working capital	51,825 (USD thousands)	⁷
2024-08-05	2025-Q1	Revolver Available	83,000	⁷
2024-08-05	2025-Q1	cash and equivalents	28,472 (USD thousands)	⁷
2024-08-05	2025-Q1	Total Net Leverage Ratio	3.41	²²
2024-08-05	2025-Q1	Gross profit percentage	64.0	²²
2024-06-28	FY2024	working capital	$65,040	⁶
2024-06-28	FY2024	credit facility outstanding	$50,500	⁶
2024-06-28	FY2024	convertible senior notes outstanding	$172,500	⁶
2024-06-28	FY2024	Cash and Cash Equivalents	$28,214	⁶
2024-06-05	FY2024	Revenues	58,904 (USD in thousands)	²¹
2024-06-05	FY2024	Operating loss	(271,284)	²¹
2024-06-05	FY2024	Net loss	(254,583)	²¹
2024-06-05	FY2024	Loss per diluted share	(47.20)	²¹
2024-06-05	FY2024	AOI per share - diluted	2.29	²¹
2024-06-05	FY2024	AOI excluding unusual items per share - diluted	2.77	²¹
2024-02-05	2024-Q3	working capital	74,172 (USD in thousands)	⁵
2024-02-05	2024-Q3	cash and equivalents	28,224 (USD in thousands)	⁵
2024-02-05	2024-Q3	Adjusted operating income excluding unusual items as a percentage of revenues	22.4%	²⁰
2023-11-06	2024-Q2	working capital Sept 30 2023	77,846 (USD thousands)	⁴
2023-11-06	2024-Q2	working capital March 31 2023	75,616 (USD thousands)	⁴
2023-11-06	2024-Q2	stock-based compensation expense six months	6,151 (USD thousands)	⁴
2023-11-06	2024-Q2	Reduction in force costs, six months	350 (USD thousands)	⁴
2023-11-06	2024-Q2	Open Market Sale Agreement capacity	150,000	⁴
2023-11-06	2024-Q2	Notes aggregate principal	172,500	⁴
2023-11-06	2024-Q2	GKE acquisition one-time costs	505 (USD thousands)	⁴
2023-11-06	2024-Q2	Expected annual savings from reduction in force	2,000	⁴
2023-11-06	2024-Q2	Expected annual interest expense, $65,000 borrowing	4,485 (USD thousands)	⁴
2023-11-06	2024-Q2	Credit Facility borrowed Oct 2023	65,000	⁴
2023-11-06	2024-Q2	Credit Facility amended amount	125,000 (USD thousands)	⁴
2023-11-06	2024-Q2	Core organic revenue growth - three months	(10.1)%	¹⁹
2023-11-06	2024-Q2	Core organic revenue growth - six months	(4.6)%	¹⁹
2023-11-06	2024-Q2	Cash and cash equivalents, Sept 30 2023	35,617 (USD thousands)	⁴
2023-11-06	2024-Q2	Cash and cash equivalents, Mar 31 2023	32,910 (USD thousands)	⁴
2023-11-06	2024-Q2	AOI excluding unusual items per diluted share	1.91	¹⁹
2023-08-03	2024-Q1	Working capital (as of Mar 31, 2023)	75,616 (USD thousands)	³
2023-08-03	2024-Q1	Working capital (as of Jun 30, 2023)	75,682 (USD thousands)	³
2023-08-03	2024-Q1	Stockholders' equity	387,719 (USD in thousands)	¹⁸
2023-08-03	2024-Q1	Revenues	50,645 (USD in thousands)	¹⁸
2023-08-03	2024-Q1	Quarterly dividend per share	0.16	³
2023-08-03	2024-Q1	Operating loss	(664)	¹⁸
2023-08-03	2024-Q1	Open purchase order commitments	17,347 (USD thousands)	³
2023-08-03	2024-Q1	Open Market Sale Agreement capacity	150,000	³
2023-08-03	2024-Q1	Net loss	(549)	¹⁸
2023-08-03	2024-Q1	Loss per share (diluted)	(0.10)	¹⁸
2023-08-03	2024-Q1	Credit Facility outstanding (as of Jun 30, 2023)	5,000	³
2023-08-03	2024-Q1	Convertible Notes outstanding (as of Jun 30, 2023)	172,500	³
2023-08-03	2024-Q1	Contingent consideration for Belyntic patents	1,500	³
2023-08-03	2024-Q1	Cash and cash equivalents (as of Mar 31, 2023)	32,910 (USD thousands)	³
2023-08-03	2024-Q1	Cash and cash equivalents (as of Jun 30, 2023)	32,376 (USD thousands)	³
2023-08-03	2024-Q1	Cash and cash equivalents	32,376 (USD in thousands)	¹⁸
2023-08-03	2024-Q1	Adjusted operating income per share (diluted)	1.77	¹⁸

▸ Earlier KPIs (+116)

Guidance Tracking (latest per metric/period · 1/1)#

All management forecasts (guidance) and their later outcome. Types: fiscal-year targets as well as quarterly/half-year targets; per metric and period the most recent statement applies, older versions can be expanded. The status is checked automatically against the actuals reported later: open (period still running), met, beaten, missed. For ranges (“X to Y”) reaching the range counts. Logged neutrally, no estimate of our own, no assessment.

For period	Guided on	Metric	Guided	Verdict	Direction	Source
2026-H1	2025-08-05	Revenue	meet revenue goals	pending	confirmed	²⁶

Development#

A condensed summary per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. Most recent period first, grouped by year; each text is written from the original report of that period, superscript numbers lead to the source.

FY2027

In its fiscal first quarter of 2027 (ended June 30, 2026), Mesa Laboratories reported total revenues of $60.1 million, a year-over-year increase of 1.0%, with core organic revenue growth returning to positive at 0.4% ³⁰. Gross profit margin expanded 290 basis points to 64.9%, primarily driven by lower third-party contracted labor spend, supply chain efficiency improvements, and favorable product mix ¹⁵. Operating income grew 129.5% to $7.0 million from $3.1 million in the prior-year period, reflecting operating efficiencies and cost-containment initiatives, while non-GAAP adjusted operating income increased 19.5% to $15.4 million, representing 25.6% of revenues ³⁰. Cash flows from operating activities rose to $14.7 million from $1.9 million in the prior-year quarter, driven by improved collections and operating performance ¹⁵. The company reduced its Total Net Leverage Ratio to 1.85, below its 2.0 target, and new CEO Siddhartha Kadia, approximately 100 days into the role, indicated full-year guidance would be provided in November ³⁰.

FY2026

Mesa Laboratories FY2026 revenues grew 3.4% to $249.1 million, with organic growth of 3.4% and core organic growth of 1.2%, driven primarily by the Sterilization and Disinfection Control division's 8.7% organic revenue increase and Calibration Solutions' 3.5% organic gain ²⁹ ¹⁴. Operating income increased 13.3% to $18.5 million and non-GAAP adjusted operating income expanded 200 basis points to 25.5% of revenues at $63.5 million ²⁹. Net income recovered to $6.7 million versus a prior-year loss of $1.9 million, supported by $39.6 million of free cash flow and a reduction in the Total Net Leverage Ratio to 2.11 at fiscal year-end ²⁹ ¹⁴. Clinical Genomics remained a headwind throughout the year as China revenues contracted 57.4% amid macroeconomic and regulatory uncertainty, partially offset by 9.1% growth outside China ²⁹. CEO Siddhartha Kadia was appointed effective April 2026 and initiated a 100-day business review ²⁹.

FY2025

Mesa Laboratories reported FY2025 consolidated revenues of $241.0 million, an increase of 11.5% from $216.2 million in fiscal year 2024, with core organic growth of 5.0% and the GKE acquisition contributing $24.8 million of inorganic revenues ¹⁰. Biopharmaceutical Development achieved 19.7% organic revenue growth, benefiting from recovered capital equipment demand in the biopharmaceutical vertical, while Clinical Genomics organic revenues declined 10.5% due to headwinds in China and U.S. regulatory constraints on lab-developed tests ¹⁰. Operating income improved to $16.3 million in FY2025 from an operating loss in FY2024 that included a $274.5 million impairment charge; on an adjusted basis, operating income grew 12.3% for the full year ²⁵. Free cash flow of $42.6 million enabled ongoing debt repayments, reducing the Net Leverage Ratio to 3.01 by fiscal year-end ²⁵. The GKE acquisition was fully integrated within nine months and exceeded initial revenue and profitability commitments, while all four divisions delivered core organic revenue growth in Q4 FY2025 ²⁵.

FY2024

Mesa Laboratories Inc. reported FY2024 total revenues of $216.2 million, a 1.3% decrease year-over-year, with core organic revenues declining 5.4% as sustained softening in life sciences capital equipment markets and the prior-year loss of major Clinical Genomics customer Sema4 weighed on results throughout the year (⁶, ²⁵). The acquisition of GKE GmbH and its China entity, completed in October and December 2023 respectively, contributed $9.3 million to the Sterilization and Disinfection Control division and partially offset organic declines (²¹). In Q4 FY2024 the company recorded $274.5 million in non-cash goodwill and long-lived asset impairment charges against the Clinical Genomics ($236.4 million) and Biopharmaceutical Development ($38.2 million) divisions, driving a GAAP full-year operating loss of $272.1 million and net loss of $254.2 million (²¹, ⁶). On an adjusted non-GAAP basis, adjusted operating income was $46.0 million for FY2024, while free cash flow of $41.6 million reflected improved working capital management versus the prior year (²⁵). The company refinanced its credit facility extending maturity to April 2029, repurchased $75.0 million of its 2025 Convertible Notes, and restructured the Clinical Genomics division under new leadership (⁶).

FY2023

Mesa Laboratories reported fiscal year 2023 revenues of $219.1 million, an 18.8% increase versus fiscal year 2022, primarily driven by the Agena Bioscience acquisition completed in October 2021; core organic revenue growth was 5.2% ¹⁷. Full-year GAAP operating income declined 29.4% to $3.3 million and net income fell 50% to $0.9 million as higher operating expenses from the Agena acquisition weighed on reported results, while adjusted operating income was $49.0 million ⁶. The Clinical Genomics division faced an approximately $8.2 million annual revenue headwind after Sema4 Holdings notified the company of its intent to exit reproductive health screening; excluding this impact, core organic growth would have been approximately 15% for the full year ¹⁷. Sterilization and Disinfection Control achieved core organic growth of 12.2% for the year, while Calibration Solutions revenues declined 4% due to raw materials supply constraints that began abating in the fourth quarter ². Free cash flow totaled $23.4 million for the year, and material weaknesses were identified in internal controls over fair value and goodwill impairment assessments as of March 31, 2023 ².

Sources: official investor relations documents#

All original documents used, with type (e.g. quarterly, half-year, annual report), publication date and a direct link to the filing (EDINET/SEC/IR). Every superscript number in the report points to an entry in this list; so every figure can be traced back to its place in the original.

46 documents · 2016 – 2026 · SEC EDGAR (USA)

#	Document type	Published	Link
#1	10-Q	2023-02-06	Open
#16	8-K-EX99.1	2023-02-06	Open
#17	8-K-EX99.1	2023-05-25	Open
#2	10-K	2023-05-30	Open
#3	10-Q	2023-08-03	Open
#18	8-K-EX99.1	2023-08-03	Open
#4	10-Q	2023-11-06	Open
#19	8-K-EX99.1	2023-11-06	Open
#5	10-Q	2024-02-05	Open
#20	8-K-EX99.1	2024-02-05	Open
#21	8-K-EX99.1	2024-06-05	Open
#6	10-K	2024-06-28	Open
#7	10-Q	2024-08-05	Open
#22	8-K-EX99.1	2024-08-05	Open
#8	10-Q	2024-11-07	Open
#23	8-K-EX99.1	2024-11-07	Open
#9	10-Q	2025-02-04	Open
#24	8-K-EX99.1	2025-02-04	Open
#10	10-K	2025-05-28	Open
#25	8-K-EX99.1	2025-05-28	Open
#11	10-Q	2025-08-05	Open
#26	8-K-EX99.1	2025-08-05	Open
#12	10-Q	2025-11-06	Open
#27	8-K-EX99.1	2025-11-06	Open
#13	10-Q	2026-02-03	Open
#28	8-K-EX99.1	2026-02-03	Open
#29	8-K-EX99.1	2026-05-27	Open
#14	10-K	2026-06-03	Open
#15	10-Q	2026-08-10	Open
#30	8-K-EX99.1	2026-08-10	Open

▸ More rows (+15)

Older sources (+16)

#	Document type	Published	Link
#202	10-K	2016-06-06	Open
#205	10-K	2016-06-06	Open
#201	10-Q	2016-11-07	Open
#206	10-K	2017-06-07	Open
#203	10-Q	2017-08-01	Open
#204	10-Q	2017-11-06	Open
#210	10-K	2019-06-03	Open
#207	10-Q	2019-07-30	Open
#208	10-Q	2019-11-06	Open
#209	10-Q	2020-02-10	Open
#214	10-K	2020-06-01	Open
#211	10-Q	2020-08-06	Open
#212	10-Q	2020-11-05	Open
#213	10-Q	2021-02-03	Open
#215	10-Q	2021-08-05	Open
#216	10-Q	2021-11-04	Open

▸ More rows (+1)

FAQ#

Does Mesa Laboratories Inc. pay a dividend?

The filings report on the dividend; most recent entry: dividend per share 0.16 (2027-Q1) (as reported, no assessment of our own). Details with source links are in the report chapters.

Where can I find the official investor relations documents of Mesa Laboratories Inc.?

The sources chapter links all 46 original filings used (SEC filings) with type, publication date and a direct link; every figure in the report carries a source number.